Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications | MicrobiomeTrials
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
TERMINATEDPHASE1INTERVENTIONAL
Trial Details
Start: 2023-03-24Est. Completion: 2026-03-17
Enrollment target: 85 participants
Locations
UCLA Medical Center, Los Angeles, California, United States
Sarcoma Oncology, Santa Monica, California, United States
HealthONE, Denver, Colorado, United States
Florida Cancer Specialists, Lake Mary, Florida, United States
The University of Kansas, Fairway, Kansas, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
START Midwest, Grand Rapids, Michigan, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
NEXT Oncology - Dallas, Irving, Texas, United States
NEXT Oncology, San Antonio, Texas, United States
NEXT Oncology, Fairfax, Virginia, United States
University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, United States
University of Wisconsin, Madison, Wisconsin, United States
Other microbiome trials you might be interested in
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Non-small Cell Lung Cancer (NSCLC)HR+/HER2- Ductal Breast Cancer (BC)HR+/HER2- Lobular Breast Cancer (BC)Triple Negative Breast Cancer (TNBC)Colorectal Cancer (CRC)